SpringerLink
Log in

Buparlisib/mk-2206

Various toxicities and off label use: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Zhao T, et al. Genetic analysis and targeted therapy using buparlisib and mk2206 in a patient with triple metachronous cancers of the kidney, prostate, and squamous cell carcinoma of the lung: A case report. OncoTargets and Therapy 14: 2839-2845, Jan 2021. Available from: URL: https://www.dovepress.com/getfile.php?fileID=68877

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buparlisib/mk-2206. Reactions Weekly 1938, 342 (2023). https://doi.org/10.1007/s40278-023-30483-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-30483-x

Search

Navigation